Overall, these data suggest that both CD8+ and CD4+ T cells in MS/CIS patients are more activated with increased effector functions and tissue homing capacity than HC/OND participants, consistent with other studies15,16,19. This evidence concerns the gene CD8A and myeloid sarcoma.